Near Infrared Imaging of EGFR of Oral Squamous Cell Carcinoma in Mice Administered Arsenic Trioxide

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Zhang, Lingbo ^a   Wang, Kezheng ^a   Zhao, Falin ^b   Hu, Weiping ^a   Chen, Junjie ^c   Lanza, Gregory M ^c   Shen, Baozhong ^a   Zhang, Bin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HANGZHOU NORMAL UNIVERSITY   (China)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NEAR INFRARED IMAGING; NONHUMAN; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BODY WEIGHT; CARBOCYANINES; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OXIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; SPECTROSCOPY, NEAR-INFRARED; TUMOR BURDEN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84867032419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046255     Document Type: Article

References (40)

1. Konkimalla VB, Suhas VL, Chandra NR, Gebhart E, Efferth T, (2007) Diagnosis and therapy of oral squamous cell carcinoma. Expert Rev Anticancer Ther 7: 317-329.
2. Sarkis SA, Abdullah BH, Abdul Majeed BA, Talabani NG, (2010) Immunohistochemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apoptosis, angiogenesis and lymphangiogenesis. Head Neck Oncol 2: 13-20.
3. Rethman MP, Carpenter W, Cohen EE, Epstein J, Evans CA, et al. (2010) Evidence-based clinical recommendations regarding screening for oral squamous cell carcinomas. J Am Dent Assoc 141: 509-520.
4. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, et al. (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328: 240-243.
5. Cantor KP, Lubin JH, (2007) Arsenic, internal cancers, and issues in inference from studies of low-level exposures in human populations. Toxicol Appl Pharmacol 222: 252-257.
6. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348.
7. Davison K, Mann KK, Waxman S, Miller WH Jr, (2004) JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103: 3496-3502.
8. Liu ZM, Tseng JT, Hong DY, Huang HS, (2011) Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells. Biochem J 438: 349-358.
9. Vernhet L, Allain N, Payen L, Anger JP, Guillouzo A, et al. (2001) Resistance of human multidrug resistance-associated protein 1-overexpressing lung tumor cells to the anticancer drug arsenic trioxide. Biochem Pharmacol 61: 1387-1391.
10. Jhala DD, Chinoy NJ, Rao MV, (2008) Mitigating effects of some antidotes on fluoride and arsenic induced free radical toxicity in mice ovary. Food Chem Toxicol 46: 1138-1142.
11. Chen X, Zhang M, Liu LX, (2009) The overexpression of multidrug resistance-associated proteins and gankyrin contribute to arsenic trioxide resistance in liver and gastric cancer cells. Oncol Rep 22: 73-80.
12. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, et al. (2001) Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61: 5432-5440.
13. Yeh KY, Chang JW, Li YY, Wang CH, Wang HM, (2011) Tumor growth inhibition of metastatic nasopharyngeal carcinoma cell lines by low dose of arsenic trioxide via alteration of cell cycle progression and induction of apoptosis. Head Neck 33: 734-742.
14. Tsai CW, Chang NW, Tsai RY, Wang RF, Hsu CM, et al. (2010) Synergistic cytotoxic effects of arsenic trioxide plus dithiothreitol on mice oral cancer cells. Anticancer Res 30: 3655-3660.
15. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H, (2002) How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2: 705-713.
16. Liu ZM, Huang HS, (2006) As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21(WAF1/CIP1) expression in human epidermoid carcinoma A431 cells. Cellular Signalling 18: 244-255.
17. Shin DM, Ro JY, Hong WK, Hittelman WN, (1994) Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54: 3153-3159.
18. Laimer K, Spizzo G, Gastl G, Obrist P, Brunhuber T, et al. (2007) High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis. Oral Oncol 43: 193-198.
19. Lippman SM, Sudbo J, Hong WK, (2005) Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 23: 346-356.
20. Cho JH, Lee MH, Cho YJ, Park BS, Kim S, et al. (2011) The bacterial protein azurin enhances sensitivity of oral squamous carcinoma cells to anticancer drugs. Yonsei Med J 52: 773-778.
21. Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, et al. (2006) Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 97: 1366-1373.
22. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, et al. (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901.
23. Gee MS, Upadhyay R, Bergquist H, Alencar H, Reynolds F, et al. (2008) Human breast cancer tumor models: Molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology 248: 925-935.
24. Wang K, Wang K, Li W, Huang T, Li R, et al. (2009) Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging. Acta Radiol 50: 1095-1103.
25. Ntziachristos V, Bremer C, Weissleder R, (2003) Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol 13: 195-208.
26. Nitin N, Rosbach KJ, El-Naggar A, Williams M, Gillenwater A, et al. (2009) Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasia. Neoplasia 11: 542-551.
27. Huang HS, Liu ZM, Ding L, Chang WC, Hsu PY, et al. (2006) Opposite effect of ERK1/2 and JNK on p53-independent p21WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity. J Biomed Sci 13: 113-125.
28. Wang ZY, Chen Z, (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515.
29. Bode AM, Dong Z, (2002) The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 42: 5-24.
30. Liu ZM, Huang HS, (2006) As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells. Cell Signal 18: 244-255.
31. Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach PH, et al. (2008) Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone. Molecular Cancer Therapeutics 7: 2060-2069.
32. Chen X, Conti PS, Moats RA, (2004) In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 64: 8009-8014.
33. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, et al. (2003) Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res 63: 7870-7875.
34. Withrow KP, Newman JR, Skipper JB, Gleysteen JP, Magnuson JS, et al. (2008) Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts. Technol Cancer Res Treat 7: 61-66.
35. Oyen WJG, van der Graaf WTA, (2009) Molecular imaging of solid tumors: exploiting the potential. Nature Reviews Clinical Oncology 6: 609-611.
36. Adams KE, Ke S, Kwon S, Liang F, Fan Z, et al. (2007) Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 12: 024017.
37. Gleysteen JP, Newman JR, Chhieng D, Frost A, Zinn KR, et al. (2008) Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model. Head Neck 30: 782-789.
38. Tichauer KM, Samkoe KS, Sexton KJ, Hextrum SK, Yang HH, et al. (2011) In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular Imaging. Mol Imaging Biol [Epub ahead of print].
39. Chou YH, Woon PY, Huang WC, Shiurba R, Tsai YT, et al. (2011) Divalent lead cations induce cyclooxygenase-2 gene expression by epidermal growth factor receptor/nuclear factor-kappa B signaling in A431carcinoma cells. Toxicol Lett 203: 147-153.
40. Rosenthal EL, Kulbersh BD, Duncan RD, Zhang W, Magnuson JS, et al. (2006) In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence. Laryngoscope 116: 1636-1641.